LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 30

Search options

  1. Book ; Thesis: Oral anticoagulation treatment in atrial fibrillation

    Wieloch, Mattias

    to bleed or not to bleed, that is the question

    (Doctoral dissertation series ; 2011,99)

    2011  

    Author's details Mattias Wieloch
    Series title Doctoral dissertation series ; 2011,99
    Collection
    Language English ; Swedish
    Size Getr. Zählung : Ill., graph. Darst.
    Publishing country Sweden
    Document type Book ; Thesis
    Thesis / German Habilitation thesis Lund, Univ., Diss., 2011
    Note Zsfassung in schwed. Sprache
    HBZ-ID HT017199520
    ISBN 978-91-86871-48-2 ; 91-86871-48-X
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  2. Article ; Online: Risk of Major Bleeding in Patients With Atrial Fibrillation Taking Dronedarone in Combination With a Direct Acting Oral Anticoagulant (From a U.S. Claims Database).

    Gandhi, Sampada K / Reiffel, James A / Boiron, Rania / Wieloch, Mattias

    The American journal of cardiology

    2021  Volume 159, Page(s) 79–86

    Abstract: Dronedarone may increase exposure and the risk of major bleeding when prescribed with a direct oral anticoagulant (DOAC). This retrospective cohort study examined the risk of the first occurrence of major bleeding (hospitalization or emergency room visit ...

    Abstract Dronedarone may increase exposure and the risk of major bleeding when prescribed with a direct oral anticoagulant (DOAC). This retrospective cohort study examined the risk of the first occurrence of major bleeding (hospitalization or emergency room visit for gastrointestinal [GI] bleeding, intracranial hemorrhage [ICH], or bleeding at other sites) among new users of apixaban, dabigatran, and rivaroxaban in patients with AF ≥18 years (January 1, 2007 to September 30, 2017) from the United States Truven Health MarketScan claims, comparing concomitant users of dronedarone to DOAC alone users in patients with atrial fibrillation (AF). No increased risk of major bleeding was associated with use of dronedarone and apixaban (adjusted Hazard Ratio [aHR]: 0.69 [95% confidence interval [CI]: 0.40, 1.17], p = 0.16), a modestly increased risk of GI bleeding but not overall bleeding was associated with use of dronedarone and dabigatran (aHR bleeding: 1.18 [95% CI: 0.89, 1.56], p = 0.26; aHR GI bleeding: 1.40 [95% CI: 1.01, 1.93]; p = 0.04) and an increased risk of overall bleeding, driven by GI bleeding, was associated with use of dronedarone and rivaroxaban (aHR bleeding: 1.31 [95% CI: 1.01, 1.69]; p = 0.04; aHR GI bleeding: 1.39 [95% CI: 0.98, 1.95]; p = 0.06), compared to each DOAC respectively. There was no increased risk of ICH associated with combined use of dronedarone and any DOAC. Prospective analyses, preferably randomized controlled studies, are needed to further explore the risk of major bleeding with concomitant use of DOACs and CYP3A4/P-gp inhibitors such as dronedarone.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Arrhythmia Agents/adverse effects ; Anti-Arrhythmia Agents/therapeutic use ; Atrial Fibrillation/drug therapy ; Cohort Studies ; Databases, Factual ; Dronedarone/adverse effects ; Dronedarone/therapeutic use ; Drug Interactions ; Drug Therapy, Combination ; Factor Xa Inhibitors/adverse effects ; Female ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Risk Assessment ; Severity of Illness Index ; United States ; Young Adult
    Chemical Substances Anti-Arrhythmia Agents ; Factor Xa Inhibitors ; Dronedarone (JQZ1L091Y2)
    Language English
    Publishing date 2021-08-28
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80014-4
    ISSN 1879-1913 ; 0002-9149
    ISSN (online) 1879-1913
    ISSN 0002-9149
    DOI 10.1016/j.amjcard.2021.08.015
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Effect of dronedarone vs. placebo on atrial fibrillation progression: a post hoc analysis from ATHENA trial.

    Blomström-Lundqvist, Carina / Naccarelli, Gerald V / McKindley, David S / Bigot, Gregory / Wieloch, Mattias / Hohnloser, Stefan H

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

    2023  Volume 25, Issue 3, Page(s) 845–854

    Abstract: Aims: This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL, and regression to sinus rhythm (SR), ... ...

    Abstract Aims: This post hoc analysis of the ATHENA trial (NCT00174785) assessed the effect of dronedarone on the estimated burden of atrial fibrillation (AF)/atrial flutter (AFL) progression to presumed permanent AF/AFL, and regression to sinus rhythm (SR), compared with placebo.
    Methods and results: The burden of AF/AFL was estimated by a modified Rosendaal method using available electrocardiograms (ECG). Cumulative incidence of permanent AF/AFL (defined as ≥6 months of AF/AFL until end of study) or permanent SR (defined as ≥6 months of SR until end of study) were calculated using Kaplan-Meier estimates. A log-rank test was used to assess statistical significance. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were estimated using a Cox model, adjusted for treatment group. Of the 4439 patients included in this analysis, 2208 received dronedarone, and 2231 placebo. Baseline and clinical characteristics were well balanced between groups. Overall, 304 (13.8%) dronedarone-treated patients progressed to permanent AF/AFL compared with 455 (20.4%) treated with placebo (P < 0.0001). Compared with those receiving placebo, patients receiving dronedarone had a lower cumulative incidence of permanent AF/AFL (log-rank P < 0.001; HR: 0.65; 95% CI: 0.56-0.75), a higher cumulative incidence of permanent SR (log-rank P < 0.001; HR: 1.19; 95% CI: 1.09-1.29), and a lower estimated AF/AFL burden over time (P < 0.01 from Day 14 to Month 21).
    Conclusion: These results suggest that dronedarone could be a useful antiarrhythmic drug for early rhythm control due to less AF/AFL progression and more regression to SR vs. placebo, potentially reflecting reverse remodeling.
    Clinical trial registration: NCT00174785.
    MeSH term(s) Humans ; Amiodarone/adverse effects ; Anti-Arrhythmia Agents/adverse effects ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/epidemiology ; Atrial Flutter/diagnosis ; Atrial Flutter/drug therapy ; Atrial Flutter/epidemiology ; Dronedarone/adverse effects ; Hospitalization
    Chemical Substances Amiodarone (N3RQ532IUT) ; Anti-Arrhythmia Agents ; Dronedarone (JQZ1L091Y2)
    Language English
    Publishing date 2023-02-08
    Publishing country England
    Document type Clinical Trial ; Journal Article
    ZDB-ID 1449879-0
    ISSN 1532-2092 ; 1099-5129
    ISSN (online) 1532-2092
    ISSN 1099-5129
    DOI 10.1093/europace/euad023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Novel methodology for the evaluation of symptoms reported by patients with newly diagnosed atrial fibrillation: Application of natural language processing to electronic medical records data.

    Reynolds, Matthew R / Bunch, Thomas Jared / Steinberg, Benjamin A / Ronk, Christopher J / Kim, Hankyul / Wieloch, Mattias / Lip, Gregory Y H

    Journal of cardiovascular electrophysiology

    2023  Volume 34, Issue 4, Page(s) 790–799

    Abstract: Introduction: Understanding symptom patterns in atrial fibrillation (AF) can help in disease management. We report on the application of natural language processing (NLP) to electronic medical records (EMRs) to capture symptom reports in patients with ... ...

    Abstract Introduction: Understanding symptom patterns in atrial fibrillation (AF) can help in disease management. We report on the application of natural language processing (NLP) to electronic medical records (EMRs) to capture symptom reports in patients with newly diagnosed (incident) AF.
    Methods and results: This observational retrospective study included adult patients with an index diagnosis of incident AF during January 1, 2016 through June 30, 2018, in the Optum datasets. The baseline and follow-up periods were 1 year before/after the index date, respectively. The primary objective was identification of the following predefined symptom reports: dyspnea or shortness of breath; syncope, presyncope, lightheadedness, or dizziness; chest pain; fatigue; and palpitations. In an exploratory analysis, the incidence rates of symptom reports and cardiovascular hospitalization were assessed in propensity-matched patient cohorts with incident AF receiving first-line dronedarone or sotalol. Among 30 447 patients with an index AF diagnosis, the NLP algorithm identified at least 1 predefined symptom in 9734 (31.9%) patients. The incidence rate of symptom reports was highest at 0-3 months post-diagnosis and lower at >3-6 and >6-12 months (pre-defined timepoints). Across all time periods, the most common symptoms were dyspnea or shortness of breath, followed by syncope, presyncope, lightheadedness, or dizziness. Similar temporal patterns of symptom reports were observed among patients with prescriptions for dronedarone or sotalol as first-line treatment.
    Conclusion: This study illustrates that NLP can be applied to EMR data to characterize symptom reports in patients with incident AF, and the potential for these methods to inform comparative effectiveness.
    MeSH term(s) Adult ; Humans ; Atrial Fibrillation/drug therapy ; Dronedarone ; Anti-Arrhythmia Agents/therapeutic use ; Sotalol ; Dizziness/drug therapy ; Retrospective Studies ; Electronic Health Records ; Natural Language Processing ; Dyspnea ; Syncope
    Chemical Substances Dronedarone (JQZ1L091Y2) ; Anti-Arrhythmia Agents ; Sotalol (A6D97U294I)
    Language English
    Publishing date 2023-01-06
    Publishing country United States
    Document type Observational Study ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1025989-2
    ISSN 1540-8167 ; 1045-3873
    ISSN (online) 1540-8167
    ISSN 1045-3873
    DOI 10.1111/jce.15784
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Evaluating the Risk of Digitalis Intoxication Associated With Concomitant Use of Dronedarone and Digoxin Using Real-World Data.

    Wu, Chuntao / Boiron, Rania / Kechemir, Hayet / Gandhi, Sampada / Lin, Stephen / Wieloch, Mattias / Juhaeri, Juhaeri

    Clinical therapeutics

    2021  Volume 43, Issue 5, Page(s) 852–858.e2

    Abstract: Purpose: Dronedarone may increase digoxin plasma levels through inhibition of P-glycoprotein. Using real-world data, we evaluated the risk of digitalis intoxication in concomitant users of dronedarone and digoxin compared digoxin-alone users.: Methods! ...

    Abstract Purpose: Dronedarone may increase digoxin plasma levels through inhibition of P-glycoprotein. Using real-world data, we evaluated the risk of digitalis intoxication in concomitant users of dronedarone and digoxin compared digoxin-alone users.
    Methods: We used the Clinformatics DataMart, a US claims database, to identify adult patients with atrial fibrillation (AF) or atrial flutter (AFL) who concomitantly used dronedarone and digoxin and those who used digoxin alone between July 2009 and March 2016. Digitalis intoxication during follow-up until March 2016 was ascertained using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Adjusted hazard ratios (HR) for digitalis intoxication in concomitant users versus users of digoxin alone were estimated, controlling for age, sex, cohort entry year, number of medical encounters for AF or AFL, history of congestive heart failure, diabetes, hypertension, stroke, myocardial infarction, renal failure, use of drugs interacting with digoxin, and digoxin dose.
    Findings: Overall, 524 concomitant users and 32,459 users of digoxin alone were identified, among which 3 and 301 events of digitalis intoxication occurred during follow-up, respectively. Incidence rates were 17.25 and 9.17 cases per 1000 person-years, respectively. The adjusted HR for digitalis intoxication in concomitant users versus users of digoxin alone was 1.56 (95% CI, 0.50-4.88; P = 0.45). When digitalis intoxication was defined by ICD-9-CM and ICD-10-CM codes accompanied by laboratory testing for digoxin/digitoxin or hospitalization within 30 days, no events occurred in the concomitant users and 40 events occurred in the users of digoxin alone (incidence rate of 1.22 cases per 1000 person-years).
    Implications: Concomitant use of dronedarone and digoxin was uncommon in this study, and no significant increase in the risk of digitalis intoxication with concomitant use was found.
    MeSH term(s) Adult ; Atrial Fibrillation/drug therapy ; Atrial Flutter ; Digitalis ; Digoxin/adverse effects ; Dronedarone ; Humans
    Chemical Substances Digoxin (73K4184T59) ; Dronedarone (JQZ1L091Y2)
    Language English
    Publishing date 2021-04-20
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 603113-4
    ISSN 1879-114X ; 0149-2918
    ISSN (online) 1879-114X
    ISSN 0149-2918
    DOI 10.1016/j.clinthera.2021.03.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Effect of Dronedarone in the Treatment of Atrial Fibrillation in the Asian Population: Post Hoc Analysis of the ATHENA Trial.

    Ma, Changsheng / Lin, Jiunn-Lee / Bai, Rong / Sun, Yihong / Nam, Gi-Byoung / Stewart, John / Wieloch, Mattias / Zhu, Jun

    Clinical therapeutics

    2022  Volume 44, Issue 9, Page(s) 1203–1213

    Abstract: Purpose: Limited data are available on the impact of dronedarone treatment in Asian patients with atrial fibrillation (AF) or atrial flutter (AFL). This post hoc analysis evaluated the efficacy and safety of dronedarone compared with placebo in ... ...

    Abstract Purpose: Limited data are available on the impact of dronedarone treatment in Asian patients with atrial fibrillation (AF) or atrial flutter (AFL). This post hoc analysis evaluated the efficacy and safety of dronedarone compared with placebo in populations from Asian and non-Asian regions randomized in the ATHENA trial (A Placebo-Controlled, Double-blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg BID for the Prevention of CV Hospitalization or Death From Any Cause in Patients With AF/AFL).
    Methods: Time to first hospitalization for cardiovascular events or death from any cause (primary outcome) and time to first AF/AFL event recurrence (secondary outcome) were analyzed by Kaplan-Meier curves and Cox proportional hazards regression.
    Findings: The risk of experiencing the primary composite outcome was significantly lower in the dronedarone-treated patients in both the Asian (hazard ratio = 0.541; 95% CI, 0.320-0.914]) and non-Asian (hazard ratio = 0.768; 95% CI, 0.696-0.848) populations than in the placebo-treated patients. The median time to the first AF/AFL event recurrence was longer in the dronedarone-treated population than in the placebo-treated populations: 183 vs 92 days (P = 0.165) in the Asian population and 534 vs 196 days (P < 0.001) in the non-Asian population. Treatment-emergent adverse events in Asian (81.2% vs 78.4%) and non-Asian (71.4% vs 68.7%) populations and serious treatment-emergent adverse events in Asian (14.3% vs 15.7%) and non-Asian (20.3% vs 21.5%) patients were comparable in patients taking dronedarone compared with those taking placebo.
    Implication: Efficacy and tolerability of dronedarone were consistent in the Asian population compared with the non-Asian population in the ATHENA trial. These finding may aid Asian health care professionals to select the appropriate first-line treatment for Asian patients with AF/AFL.
    MeSH term(s) Amiodarone/adverse effects ; Anti-Arrhythmia Agents/adverse effects ; Atrial Fibrillation/drug therapy ; Atrial Flutter/drug therapy ; Dronedarone/adverse effects ; Humans ; Treatment Outcome
    Chemical Substances Anti-Arrhythmia Agents ; Dronedarone (JQZ1L091Y2) ; Amiodarone (N3RQ532IUT)
    Language English
    Publishing date 2022-08-01
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 603113-4
    ISSN 1879-114X ; 0149-2918
    ISSN (online) 1879-114X
    ISSN 0149-2918
    DOI 10.1016/j.clinthera.2022.07.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies.

    Handelsman, Yehuda / Bunch, T Jared / Rodbard, Helena W / Steinberg, Benjamin A / Thind, Munveer / Bigot, Gregory / Konigsberg, Lana / Wieloch, Mattias / Kowey, Peter R

    Journal of diabetes and its complications

    2022  Volume 36, Issue 7, Page(s) 108227

    Abstract: Aim: This post hoc analysis evaluated efficacy and safety of dronedarone in atrial fibrillation (AF) and atrial flutter (AFL) patients with/without diabetes.: Methods: Patients were categorized according to baseline diabetes status. Time-to-event ... ...

    Abstract Aim: This post hoc analysis evaluated efficacy and safety of dronedarone in atrial fibrillation (AF) and atrial flutter (AFL) patients with/without diabetes.
    Methods: Patients were categorized according to baseline diabetes status. Time-to-event analyses were performed using Kaplan-Meier method. Hazard-ratios were assessed using Cox models.
    Results: 945/4628 (dronedarone = 482; placebo = 463) patients in ATHENA and 215/1237 (dronedarone = 148; placebo = 67) patients in EURIDIS/ADONIS studies had diabetes. In ATHENA, there were higher rates of CV hospitalization/death in patients with diabetes (39.5%) than without diabetes (34.7%). Incidence of first CV hospitalization/death was lower in patients with diabetes treated with dronedarone (35.1%) than placebo (44.1%), and time to this event was longer in those treated with dronedarone than placebo (log-rank p = 0.005). Median AF/AFL recurrence time was longer in patients treated with dronedarone than placebo in patients with diabetes (ATHENA: 722 vs 527 days, log-rank p = 0.004; EURIDIS/ADONIS: 100 vs 23 days, log-rank p = 0.15) or without diabetes (ATHENA: 741 vs 492 days, log-rank p < 0.0001; EURIDIS/ADONIS: 120 vs 59 days, log-rank p = 0.0002). Occurrence of any treatment-related adverse events with dronedarone was similar for patients with/without diabetes and was comparable to placebo.
    Conclusions: Dronedarone reduced incidence of CV hospitalization/death, AF/AFL recurrence and increased time to these events in AF/AFL patients with/without diabetes.
    Trial registration: Not applicable, as it was a post hoc analysis. This article is based on previously conducted studies (ATHENA: NCT00174785, EURIDIS: NCT00259428, and ADONIS: NCT00259376).
    MeSH term(s) Adonis ; Amiodarone/adverse effects ; Anti-Arrhythmia Agents/adverse effects ; Atrial Fibrillation/complications ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/epidemiology ; Diabetes Mellitus/drug therapy ; Diabetes Mellitus/epidemiology ; Dronedarone/adverse effects ; Humans
    Chemical Substances Anti-Arrhythmia Agents ; Dronedarone (JQZ1L091Y2) ; Amiodarone (N3RQ532IUT)
    Language English
    Publishing date 2022-06-08
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1105840-7
    ISSN 1873-460X ; 1056-8727
    ISSN (online) 1873-460X
    ISSN 1056-8727
    DOI 10.1016/j.jdiacomp.2022.108227
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Dronedarone Versus Sotalol in Antiarrhythmic Drug-Naive Veterans With Atrial Fibrillation.

    Pundi, Krishna / Fan, Jun / Kabadi, Shaum / Din, Natasha / Blomström-Lundqvist, Carina / Camm, A John / Kowey, Peter / Singh, Jagmeet P / Rashkin, Jason / Wieloch, Mattias / Turakhia, Mintu P / Sandhu, Alexander T

    Circulation. Arrhythmia and electrophysiology

    2023  Volume 16, Issue 8, Page(s) 456–467

    Abstract: Background: Sotalol and dronedarone are both used for maintenance of sinus rhythm for patients with atrial fibrillation. However, while sotalol requires initial monitoring for QT prolongation and proarrhythmia, dronedarone does not. These treatments can ...

    Abstract Background: Sotalol and dronedarone are both used for maintenance of sinus rhythm for patients with atrial fibrillation. However, while sotalol requires initial monitoring for QT prolongation and proarrhythmia, dronedarone does not. These treatments can be used in comparable patients, but their safety and effectiveness have not been compared head to head. Therefore, we retrospectively evaluated the effectiveness and safety using data from a large health care system.
    Methods: Using Veterans Health Administration data, we identified 11 296 antiarrhythmic drug-naive patients with atrial fibrillation prescribed dronedarone or sotalol in 2012 or later. We excluded patients with prior conduction disease, pacemakers or implantable cardioverter-defibrillators, ventricular arrhythmia, cancer, renal failure, liver disease, or heart failure. We used natural language processing to identify and compare baseline left ventricular ejection fraction between treatment arms. We used 1:1 propensity score matching, based on patient demographics, comorbidities, and medications, and Cox regression to compare strategies. To evaluate residual confounding, we performed falsification analysis with nonplausible outcomes.
    Results: The matched cohort comprised 6212 patients (3106 dronedarone and 3106 sotalol; mean [±SD] age, 71±10 years; 2.5% female; mean [±SD] CHA
    Conclusions: Dronedarone, compared with sotalol, was associated with a lower risk of ventricular proarrhythmic events and conduction disorders while having no difference in risk of incident cardiovascular hospitalization and mortality. These observational data provide the basis for prospective efficacy and safety trials.
    MeSH term(s) Female ; Humans ; Middle Aged ; Aged ; Aged, 80 and over ; Male ; Anti-Arrhythmia Agents/adverse effects ; Dronedarone/adverse effects ; Sotalol/adverse effects ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/chemically induced ; Retrospective Studies ; Prospective Studies ; Stroke Volume ; Veterans ; Ventricular Function, Left ; Amiodarone/adverse effects
    Chemical Substances Anti-Arrhythmia Agents ; Dronedarone (JQZ1L091Y2) ; Sotalol (A6D97U294I) ; Amiodarone (N3RQ532IUT)
    Language English
    Publishing date 2023-07-24
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2426129-4
    ISSN 1941-3084 ; 1941-3149
    ISSN (online) 1941-3084
    ISSN 1941-3149
    DOI 10.1161/CIRCEP.123.011893
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Amino acids predict prognosis in patients with acute dyspnea.

    Wiklund, Karolin / Gränsbo, Klas / Almgren, Peter / Peyman, Marjaneh / Tegnér, Lena / Toni-Bengtsson, Maria / Wieloch, Mattias / Melander, Olle

    BMC emergency medicine

    2021  Volume 21, Issue 1, Page(s) 127

    Abstract: Background: To identify amino acids that can predict risk of 90-day mortality in patients with acute dyspnea.: Method: Plasma levels of nine amino acids were analyzed 663 adult patients admitted to the Emergency Department (ED) with acute dyspnea. ... ...

    Abstract Background: To identify amino acids that can predict risk of 90-day mortality in patients with acute dyspnea.
    Method: Plasma levels of nine amino acids were analyzed 663 adult patients admitted to the Emergency Department (ED) with acute dyspnea. Cox proportional hazards models were used to examine the relation between amino acid levels and the risk of 90-day mortality.
    Result: Eighty patients (12.1%) died within 90 days of admission. An "Amino Acid Mortality Risk Score" (AMRS), summing absolute plasma levels of glycine, phenylalanine and valine, demonstrated that among the patients belonging to quartile 1 (Q1) of the AMRS, only 4 patients died, compared to 44 patients in quartile 4. Using Q1 of the AMRS as reference, each increment of 1 SD in the AMRS was associated with a hazard ratio (HR) of 2.15 for 90-day mortality, and the HR was > 9 times higher in Q4.
    Conclusion: Glycine, phenylalanine and valine are associated with a risk of 90-day mortality in patients admitted to the ED for acute dyspnea, suggesting that these amino acids may be useful in risk assessments.
    MeSH term(s) Adult ; Amino Acids ; Biomarkers ; Dyspnea ; Emergency Service, Hospital ; Humans ; Prognosis
    Chemical Substances Amino Acids ; Biomarkers
    Language English
    Publishing date 2021-10-30
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1471-227X
    ISSN (online) 1471-227X
    DOI 10.1186/s12873-021-00519-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Skåne Emergency Department Assessment of Patient Load (SEAL)-A Model to Estimate Crowding Based on Workload in Swedish Emergency Departments.

    Wretborn, Jens / Khoshnood, Ardavan / Wieloch, Mattias / Ekelund, Ulf

    PloS one

    2015  Volume 10, Issue 6, Page(s) e0130020

    Abstract: Objectives: Emergency department (ED) crowding is an increasing problem in many countries. The purpose of this study was to develop a quantitative model that estimates the degree of crowding based on workload in Swedish EDs.: Methods: At five ... ...

    Abstract Objectives: Emergency department (ED) crowding is an increasing problem in many countries. The purpose of this study was to develop a quantitative model that estimates the degree of crowding based on workload in Swedish EDs.
    Methods: At five different EDs, the head nurse and physician assessed the workload on a scale from 1 to 6 at randomized time points during a three week period in 2013. Based on these assessments, a regression model was created using data from the computerized patient log system to estimate the level of crowding based on workload. The final model was prospectively validated at the two EDs with the largest census.
    Results: Workload assessments and data on 14 variables in the patient log system were collected at 233 time points. The variables Patient hours, Occupancy, Time waiting for the physician and Fraction of high priority (acuity) patients all correlated significantly with the workload assessments. A regression model based on these four variables correlated well with the assessed workload in the initial dataset (r2 = 0.509, p < 0.001) and with the assessments in both EDs during validation (r2 = 0.641; p < 0.001 and r2 = 0.624; p < 0.001).
    Conclusions: It is possible to estimate the level of crowding based on workload in Swedish EDs using data from the patient log system. Our model may be applicable to EDs with different sizes and characteristics, and may be used for continuous monitoring of ED workload. Before widespread use, additional validation of the model is needed.
    MeSH term(s) Crowding ; Emergency Service, Hospital/statistics & numerical data ; Models, Statistical ; Regression Analysis ; Reproducibility of Results ; Surveys and Questionnaires ; Sweden ; Workload/statistics & numerical data
    Language English
    Publishing date 2015
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1932-6203
    ISSN (online) 1932-6203
    DOI 10.1371/journal.pone.0130020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top